Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Fig. 6 | Breast Cancer Research

Fig. 6

From: A kinase inhibitor screen identifies a dual cdc7/CDK9 inhibitor to sensitise triple-negative breast cancer to EGFR-targeted therapy

Fig. 6

Co-treatment of TNBC cells with lapatinib and PHA-767491 inhibits crucial signalling networks in TNBC. a Global transcriptomic signature in SKBR7 and Hs578T cells after 6 h of treatment with lapatinib (3.16 μM), PHA-767491 (1 μM) or a combination of these two doses. Log2 fold change (FC) normalised to DMSO control shown. b Venn diagrams showing the number of genes significantly (Log2 FC ≥ 0.5) up- or downregulated after monotherapy and combination therapy in Hs578T and SKBR7 cells. c Venn diagrams showing the number of genes commonly and significantly (Log2 FC ≥ 0.5) up- or downregulated after combination therapy in both Hs578T and SKBR7 cells. d Top canonical pathways enriched in 845 significantly differentially expressed genes in combination therapy as predicted by IPA online analysis. Z-score indicates activation (orange) or inhibition (blue) of the pathway under indicated conditions, respectively. e Top bio-functions enriched in 845 significantly differentially expressed genes in combination therapy conditions as predicted by IPA software

Back to article page